Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Debt by Year
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock carried $54.5M in long-term debt against $79.4M in cash and equivalents at the end of fiscal year 2025. This represents a decrease of 6.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
FBIOP Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $54.5M-6.0% | $58.0M-4.8% | $60.9M-33.7% | $91.7M+113.6% | $42.9M-16.9% | $51.7M-39.0% | $84.7M+0.3% | $84.4M+25.0% | $67.5M+123.5% | $30.2M+25.9% | $24.0M+71.4% | $14.0M | N/A | N/A | N/A |
| Cash & Equivalents | $79.4M+38.6% | $57.3M-29.2% | $80.9M-54.6% | $178.3M-41.7% | $305.7M+31.0% | $233.4M+70.5% | $136.9M+108.9% | $65.5M-31.0% | $95.0M-9.7% | $105.2M+7.1% | $98.2M+97.3% | $49.8M-50.0% | $99.5M+147.6% | $40.2M+73.6% | $23.2M |
FBIOP Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $35.0M-30.0% | $37.5M-33.5% | $54.5M-6.0% | $47.8M-9.0% | $50.0M-25.3% | $56.4M-8.2% | $58.0M-4.8% | $52.5M+14.6% | $67.0M+21.2% | $61.4M-33.5% | $60.9M-33.7% | $45.8M-49.8% |
| Cash & Equivalents | $196.6M+164.3% | $255.8M+180.1% | $79.4M+38.6% | $86.2M+46.5% | $74.4M-2.4% | $91.3M+9.0% | $57.3M-29.2% | $58.9M-18.6% | $76.2M-2.3% | $83.8M-45.1% | $80.9M-54.6% | $72.3M-65.3% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock financials
Frequently Asked Questions
What was Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock's long-term debt in fiscal year 2025?
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock carried $54.5M in long-term debt against $79.4M in cash and equivalents at the end of fiscal year 2025.
How fast is Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock's long-term debt growing?
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) long-term debt fell by 6.0% year over year, from $58.0M to $54.5M in fiscal year 2025.
What was Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock's long-term debt in the most recent quarter?
Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) reported $35.0M in long-term debt in Q2 2026. This represents a decrease of 30.0% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) reported on that line in every period on record.